期刊
CANCER SCIENCE
卷 111, 期 9, 页码 3132-3141出版社
WILEY
DOI: 10.1111/cas.14541
关键词
esophageal cancer; immune checkpoint inhibitors; immune microenvironment; squamous cell carcinoma; tumor immunity
类别
资金
- JSPS KAKENHI [17H04273, 17K19702, 17KK0195]
- Grants-in-Aid for Scientific Research [17K19702, 17H04273, 17KK0195] Funding Source: KAKEN
Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer, predominantly constituting 90% of cases worldwide. Despite the development of multidisciplinary therapeutic approaches, its prognosis remains unfavorable. Recently, the development of monoclonal antibodies inhibiting programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) has led to marked therapeutic responses among multiple malignancies including ESCC. However, only a few patients achieved clinical benefits due to resistance. Therefore, precise and accurate predictive biomarkers should be identified for personalized immunotherapy in clinical settings. Because the tumor immune microenvironment can potentially influence the patient's response to immune checkpoint inhibitors, tumor immunity, such as PD-L1 expression on tumors, tumor-infiltrating lymphocytes, tumor-associated macrophages, and myeloid-derived suppressor cells, in ESCC should be further investigated. In this review, accumulated evidence regarding the tumor immune microenvironment and immune checkpoint inhibitors in ESCC are summarized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据